Seeding and scaling Ontario’s premiere entrepreneurial ventures for patients and the economy.
Our investments have resulted in significant partnerships, clinical trials, job creation and leveraged financing for the province.
Keep up to date on our investments and business developments in recent news stories and summaries.
October 10, 2024 – cTRL Therapeutics announced it is strengthening its research and development operations in Canada. Following an investment by FACIT, the company will establish a state-of-the-art laboratory and leverage Ontario’s world-leading cancer research network to accelerate advancement of its cancer therapeutics pipeline to benefit patients sooner. Read More from FACIT investment in cTRL…
September 27, 2024 – Hyivy Health announced the closing of a seed financing round to advance their game-changing Pelvic Health Rehabilitation System. Hyivy will now complete clinical trials and seek regulatory approval allowing their technology to benefit patients recovering from gynecological and colorectal cancers. Read More from Hyivy Health raises seed financing to modernize pelvic…
September 11, 2024 – FACIT seeded start-up, Radiant Biotherapeutics (“Radiant”), announced the closing of Series A financing to advance the company’s proprietary multi-specific therapeutics for patients with complex cancers. Radiant’s unique multi-valent antibody platform, called Multabody™, generates best-in-class antibodies with superior potency against multiple target sites implicated in heterogenous diseases such as cancers and can…
September 5, 2024 – FACIT congratulates HDAX Therapeutics (“HDAX”) on the closing of a seed financing round to develop their best-in-class HDAC therapeutics for the treatment of a serious cancer conditions. Capital from the investor group, which included an investment from FACIT’s Compass Rose Oncology Fund, will empower HDAX to address the debilitating neuropathic pain…
June 27, 2024 – Importance of FACIT and other seed stage venture groups in building the local innovation ecosystem. Life sciences commercialization in Canada has a seed venture financing gap where companies fail to establish local roots and intellectual property gravitates to the US, reinforcing the export of jobs and industry experience. Read More from…
May 15, 2024 – FACIT President discusses early-stage investing in Canada in an interview with Newsweek’s Investment Reports and appeared in The New Era of Life Sciences 2024. FACIT is an innovative organization focused on bridging the gap between cancer research breakthroughs and their commercialization, thereby accelerating the journey of scientific discoveries from the laboratory…
We were established by the Ontario Institute for Cancer Research (OICR) to support commercialization, technology transfer, and development activities. OICR conducts and enables world-class cancer research, filling a critical role as a pan-provincial connector of oncology researchers, resources and cancer innovation development. Together with OICR, we drive a shared vision to attract more R&D investment in Ontario and help the best oncology innovations reach the market and save lives.
FACIT is funded in part by the Government of Ontario through OICR